|
Objective: Breast cancer is the most common malignancy, surgical treatment of choice in patients with early breast cancer, there may still be tiny body after subclinical metastasis foci, some of which patients will relapse or metastasis, so adjuvant therapy seem particularly important. Surgical center, chemotherapy, radiotherapy, endocrine therapy as adjuvant multidisciplinary individualized treatment model makes breast cancer recurrence and mortality was significantly reduced. There are indications for adjuvant therapy for breast cancer patients, how can we be just the right treatment, effectively avoid wrong treatment, inadequate treatment and over-treatment, individualized treatment is the core and key. Therefore Jiangsu Province Tumor Hospital Chemotherapy Dr. Huang Xinen individualized treatment of breast cancer development software. In this paper, a retrospective analysis of survival, to verify the clinical value of the software. Methods: The subjects were in Jiangsu Province Tumor Hospital of breast cancer resection, postoperative pathological diagnosis of breast cancer and receiving adjuvant therapy. Inclusion criteria; has a complete medical data, including diagnosis of age, tumor size, histological grade, lymph node metastasis, vascular infiltration, estrogen receptor / progesterone receptor (ER / PR) and human epidermal growth factor receptor body 2 (HER-2) state, and survival time. Enrolled patients were divided into 3 groups; A Group: actual treatment programs and software predicted exactly. Group B: Effective treatment programs to predict some of the same software. Group C: actual treatment programs and software prediction is completely different. Through analysis and comparison A, B, C group survival differences between the individual treatment of breast cancer to verify the validity and clinical utility software. Results: From December 1992 - July 2007, met inclusion criteria were randomly selected 310 cases of female breast cancer patients into the study. A, B, C group, the number of patients were 112,106,89 case. By plotting survival curves were used for survival analysis found that in group A and group B (P = 0.0004), A group and C group (P = 0.0046) survival differences were statistically significant. The prognosis of patients in group A were better than B and C groups. Conclusion: Postoperative adjuvant chemotherapy for breast cancer, there are many clinical programs to choose from. Choose whether to recommend adjuvant therapy and treatment programs which often depends on the subjective judgment of the doctor, so that human error is inevitable, mainly for lack of treatment, wrong treatment, and over-treatment. Software individualized treatment of breast cancer appears to provide clinicians with an objective treatment of reference, to avoid subjective bias. Through this analysis of 310 cases of breast cancer survival study, we can find individual therapy software can help develop objective and effective treatment strategies, thus prolonging survival of breast cancer patients, to avoid under-treated, error treatment and over-treatment. Thus adjuvant chemotherapy for breast cancer patients provide valuable clinical guidelines, with a good practical value, should be widely applied.
|